This study aimed to report the projected cancer incidence and mortality for the year 2022 to estimate Korea’s current cancer burden.
Cancer incidence data from 1999 to 2019 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2020 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2022. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend.
In total, 274,488 new cancer cases and 81,277 cancer deaths are expected to occur in Korea in 2022. The most common cancer site is expected to be the thyroid, followed by the lung, colon and rectum, breast, and stomach. These five cancers are expected to represent half of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and gallbladder cancers.
The incidence rates for all types of cancer in Korea are estimated to gradually decrease. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.
As the leading cause of death in Korea [
The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, known as the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [
The cancer sites included in this study were (1) all cancer sites combined and (2) the 24 cancer sites as follows: lips, oral cavity, and pharynx (C00–C14), esophagus (C15), stomach (C16), colon and rectum (C18–C20), liver (C22), gallbladder etc. (C23–C24), pancreas (C25), larynx (C32), lung (C33–C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70–C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82–C86, C96), multiple myeloma (C90), leukemia (C91–C95), and other and ill-defined sites (remainder of C00–C96).
The population data from 1993 to 2022 were obtained from the resident registration population data, reported by Statistics Korea. Data of the mid-year population (July 1 of the respective year) were used as the denominator to obtain the annual incidence and mortality rates. However, for the year 2022, we used the population data on December 31, 2020, as the mid-2022 resident registration population data were not yet available at the time of the analysis.
Linear regression models [
We summarized the results using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [
In total, 274,488 new cancer cases are expected to occur in 2022 (
The projected CRs per 100,000 for all of the sites combined in 2022 are 561.2 cases and 502.1 cases for men and women, respectively (
The five most common cancer sites expected in 2022 according to sex and age group are shown in
It is estimated that 81,277 cancer deaths will occur in Korea during 2022 (
The predicted age-specific mortality rates of the leading causes of cancer-associated death in men and women in 2022 are shown in detail in
A total of 274,488 new cancer cases and 81,277 cancer deaths are expected to occur in Korea during 2022. Prostate cancer is predicted to be the most common type of cancer among men, followed by lung, stomach, colorectal, and liver cancers. Lung, liver, colorectal, pancreatic, and stomach cancers are expected to be the most common causes of cancer deaths among men. In women, the five leading primary cancer sites are expected to be the breast, thyroid, colon and rectum, lung, and stomach, while lung, colorectal, pancreatic, breast, and liver cancers are projected to be the most common causes of cancer deaths.
Cancer is currently one of the foremost public health concerns in Korea. Although cancer incidence rates are anticipated to slightly decrease, the burden of most types of cancers will continue to grow with the increasing age of the population. The current projections of cancer incidence and mortality for 2022 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are model-based, these results should be interpreted with caution.
The authors would like to thank the tumor registrars (health information managers) of the KCCR-affiliated hospitals and non-KCCR-affiliated hospitals for the assistance with data collection, abstraction, and coding. Additionally, we acknowledge the cooperation of the National Health Insurance Service and Statistics Korea for their support with the data.
This work was supported by the National Cancer Center research grant (No. 2211110).
Conceived and designed the analysis: Won YJ.
Contributed data or analysis tools: Jung KW, Won YJ, Kong HJ.
Performed the analysis: Jung KW.
Wrote the paper: Jung KW, Won YJ.
Interpretation and review: Kang MJ.
Review and comment: Im JS, Seo HG.
Conflict of interest relevant to this article was not reported.
The 10 leading types of estimated new cancer cases and deaths by sex in 2022. (A) Estimated new cases. (B) Estimated deaths.
Projected age-specific incidences of major cancers during 2022 in Korea. (A) Men. (B) Women.
Projected age-specific mortality rates of major cancers during 2022 in Korea. (A) Men. (B). Women.
Estimated new cancer cases and deaths by sex during 2022 in Korea
Site | Estimated new cases | Estimated deaths | ||||
---|---|---|---|---|---|---|
Both sexes | Men | Women | Both sexes | Men | Women | |
All sites | 274,488 | 144,487 | 130,001 | 81,277 | 49,648 | 31,629 |
Lip, oral cavity, and pharynx | 4,212 | 3,024 | 1,188 | 1,270 | 922 | 348 |
Esophagus | 2,742 | 2,421 | 321 | 1,244 | 1,103 | 141 |
Stomach | 26,422 | 17,590 | 8,832 | 5,441 | 3,578 | 1,863 |
Colon and rectum | 29,165 | 17,187 | 11,978 | 8,790 | 4,873 | 3,917 |
Liver |
14,493 | 10,782 | 3,711 | 9,549 | 6,994 | 2,555 |
Gallbladder |
8,558 | 4,606 | 3,952 | 5,540 | 3,017 | 2,523 |
Pancreas | 9,238 | 4,756 | 4,482 | 7,277 | 3,730 | 3,547 |
Larynx | 1,058 | 999 | 59 | 217 | 217 | 0 |
Lung |
33,294 | 21,837 | 11,457 | 18,320 | 13,606 | 4,714 |
Breast | 28,142 | 110 | 28,032 | 2,909 | 19 | 2,890 |
Cervix uteri | 2,971 | - | 2,971 | 749 | - | 749 |
Corpus uteri | 3,640 | - | 3,640 | 418 | - | 418 |
Ovary | 3,173 | - | 3,173 | 1,392 | - | 1,392 |
Prostate | 22,391 | 22,391 | - | 2,278 | 2,278 | - |
Testis | 337 | 337 | - | 18 | 18 | - |
Kidney | 6,952 | 4,873 | 2,079 | 1,068 | 711 | 357 |
Bladder | 5,120 | 4,190 | 930 | 1,707 | 1,303 | 404 |
Brain and CNS | 2,185 | 1,178 | 1,007 | 1,406 | 732 | 674 |
Thyroid | 33,884 | 8,955 | 24,929 | 336 | 102 | 234 |
Hodgkin lymphoma | 354 | 217 | 137 | 62 | 38 | 24 |
Non-Hodgkin lymphoma | 6,038 | 3,477 | 2,561 | 2,314 | 1,325 | 989 |
Multiple myeloma | 2,120 | 1,116 | 1,004 | 946 | 533 | 413 |
Leukemia | 3,983 | 2,301 | 1,682 | 2,116 | 1,239 | 877 |
Other and ill defined | 24,016 | 12,140 | 11,876 | 5,910 | 3,310 | 2,600 |
CNS, central nervous system.
Includes the liver and intrahepatic bile duct,
Includes the gallbladder and other/unspecified parts of the biliary tract,
Includes the lung and bronchus.
Estimated crude and age-standardized cancer incidences by sex during 2022 in Korea
Site | Crude incidence rates per 100,000 | Age-standardized incidence rates per 100,000 | ||||
---|---|---|---|---|---|---|
Both sexes | Men | Women | Both sexes | Men | Women | |
All sites | 531.6 | 561.2 | 502.1 | 276.7 | 289.9 | 276.1 |
Lip, oral cavity, and pharynx | 8.2 | 11.8 | 4.6 | 4.3 | 6.3 | 2.5 |
Esophagus | 5.3 | 9.4 | 1.2 | 2.4 | 4.4 | 0.6 |
Stomach | 51.2 | 68.3 | 34.1 | 24.0 | 34.0 | 15.3 |
Colon and rectum | 56.5 | 66.8 | 46.3 | 26.4 | 33.8 | 19.8 |
Liver |
28.1 | 41.9 | 14.3 | 12.9 | 20.9 | 5.7 |
Gallbladder |
16.6 | 17.9 | 15.3 | 6.6 | 8.3 | 5.3 |
Pancreas | 17.9 | 18.5 | 17.3 | 7.7 | 8.9 | 6.7 |
Larynx | 2.1 | 3.9 | 0.2 | 0.9 | 1.8 | 0.1 |
Lung |
64.5 | 84.8 | 44.3 | 27.6 | 39.4 | 18.6 |
Breast | 54.5 | 0.4 | 108.3 | 33.1 | 0.2 | 66.1 |
Cervix uteri | 5.8 | - | 11.5 | 3.7 | - | 7.4 |
Corpus uteri | 7.1 | - | 14.1 | 4.2 | - | 8.3 |
Ovary | 6.1 | - | 12.3 | 3.7 | - | 7.4 |
Prostate | 43.4 | 87.0 | - | 18.4 | 40.3 | - |
Testis | 0.7 | 1.3 | - | 0.7 | 1.3 | - |
Kidney | 13.5 | 18.9 | 8.0 | 7.4 | 10.8 | 4.2 |
Bladder | 9.9 | 16.3 | 3.6 | 4.1 | 7.6 | 1.3 |
Brain and CNS | 4.2 | 4.6 | 3.9 | 3.0 | 3.4 | 2.7 |
Thyroid | 65.6 | 34.8 | 96.3 | 47.6 | 24.8 | 71.2 |
Hodgkin lymphoma | 0.7 | 0.8 | 0.5 | 0.6 | 0.7 | 0.5 |
Non-Hodgkin lymphoma | 11.7 | 13.5 | 9.9 | 6.7 | 8.3 | 5.4 |
Multiple myeloma | 4.1 | 4.3 | 3.9 | 1.8 | 2.1 | 1.6 |
Leukemia | 7.7 | 8.9 | 6.5 | 5.7 | 6.7 | 4.6 |
Other and ill defined | 46.5 | 47.2 | 45.9 | 23.2 | 25.9 | 20.9 |
CNS, central nervous system.
ge adjusted to the world standard population,
Includes the liver and intrahepatic bile duct,
Includes the gallbladder and other/unspecified parts of the biliary tract,
Includes the lung and bronchus.
Estimated cancer incidence by age group and sex during 2022 in Korea
Rank | Age group (yr) | |||
---|---|---|---|---|
0–14 | 15–34 | 35–64 | ≥65 | |
1 | Leukemia (4.8) | Thyroid (25.0) | Colon and rectum (63.8) | Prostate (453.6) |
2 | Non-Hodgkin lymphoma (3.2) | Leukemia (4.0) | Stomach (63.2) | Lung |
3 | Brain and CNS (2.3) | Colon and rectum (3.8) | Thyroid (51.0) | Stomach (252.4) |
4 | Kidney (0.3) | Non-Hodgkin lymphoma (3.3) | Lung |
Colon and rectum (234.5) |
5 | Liver (0.3) | Testis (3.1) | Liver |
Liver |
1 | Leukemia (4.0) | Thyroid (75.1) | Breast (179.0) | Lung |
2 | Brain and CNS (2.1) | Breast (12.8) | Thyroid (146.4) | Colon and rectum (143.2) |
3 | Non-Hodgkin lymphoma (1.7) | Cervix uteri (5.4) | Colon and rectum (38.7) | Breast (113.3) |
4 | Ovary (0.8) | Ovary (3.6) | Lung |
Stomach (100.4) |
5 | Thyroid (0.6) | Corpus uteri (3.0) | Stomach (31.1) | Pancreas (66.4) |
CNS, central nervous system.
Includes the lung and bronchus,
Includes the liver and intrahepatic bile duct.
Estimated crude and age-standardized cancer mortality rates by sex during 2022 in Korea
Site | Crude mortality rates per 100,000 | Age-standardized mortality rates per 100,000 | ||||
---|---|---|---|---|---|---|
Both sexes | Men | Women | Both sexes | Men | Women | |
All sites | 157.4 | 192.8 | 122.2 | 63.3 | 89.1 | 44.0 |
Lip, oral cavity, and pharynx | 2.5 | 3.6 | 1.3 | 1.1 | 1.7 | 0.5 |
Esophagus | 2.4 | 4.3 | 0.5 | 1.0 | 1.9 | 0.2 |
Stomach | 10.5 | 13.9 | 7.2 | 4.1 | 6.5 | 2.2 |
Colon and rectum | 17.0 | 18.9 | 15.1 | 6.6 | 8.8 | 4.7 |
Liver |
18.5 | 27.2 | 9.9 | 7.7 | 13.0 | 3.2 |
Gallbladder |
10.7 | 11.7 | 9.7 | 3.9 | 5.2 | 2.8 |
Pancreas | 14.1 | 14.5 | 13.7 | 5.6 | 6.8 | 4.6 |
Larynx | 0.4 | 0.8 | 0.0 | 0.2 | 0.4 | 0.0 |
Lung |
35.5 | 52.9 | 18.2 | 13.4 | 23.4 | 5.9 |
Breast | 5.6 | 0.1 | 11.2 | 2.9 | 0.0 | 5.7 |
Cervix uteri | 1.5 | - | 2.9 | 0.7 | - | 1.4 |
Corpus uteri | 0.8 | - | 1.6 | 0.4 | - | 0.8 |
Ovary | 2.7 | - | 5.4 | 1.3 | - | 2.5 |
Prostate | 4.4 | 8.9 | - | 1.4 | 3.8 | - |
Testis | 0.0 | 0.1 | - | 0.0 | 0.1 | - |
Kidney | 2.1 | 2.8 | 1.4 | 0.9 | 1.3 | 0.5 |
Bladder | 3.3 | 5.1 | 1.6 | 1.1 | 2.2 | 0.4 |
Brain and CNS | 2.7 | 2.8 | 2.6 | 1.5 | 1.7 | 1.4 |
Thyroid | 0.7 | 0.4 | 0.9 | 0.2 | 0.2 | 0.3 |
Hodgkin lymphoma | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
Non-Hodgkin lymphoma | 4.5 | 5.2 | 3.8 | 1.8 | 2.4 | 1.3 |
Multiple myeloma | 1.8 | 2.1 | 1.6 | 0.7 | 0.9 | 0.5 |
Leukemia | 4.1 | 4.8 | 3.4 | 1.9 | 2.5 | 1.5 |
Other and ill defined | 11.4 | 12.9 | 10.0 | 4.8 | 6.3 | 3.5 |
CNS, central nervous system.
Age adjusted to the world standard population,
Includes the liver and intrahepatic bile duct,
Includes the gallbladder and other/unspecified parts of the biliary tract,
Includes the lung and bronchus.